Jerome Giustiniani

Creteil, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre.

Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre.

Journal: Immunology letters

Published: February 29, 2024

Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas.

Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas.

Journal: The Journal of investigative dermatology

Published: January 26, 2024

Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.

Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.

Journal: Breast cancer research : BCR

Published: November 13, 2023

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

Journal: Haematologica

Published: October 04, 2022

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.

The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.

Journal: Cancer immunology, immunotherapy : CII

Published: December 24, 2021

CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.

CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.

Journal: Blood advances

Published: November 01, 2021

PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?

PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 15, 2021

Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit.

Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit.

Journal: Stem cells translational medicine

Published: November 06, 2018

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.

Journal: Investigative ophthalmology & visual science

Published: June 04, 2018

CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases.

CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases.

Journal: Investigative ophthalmology & visual science

Published: June 04, 2018

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Journal: Scientific reports

Published: October 21, 2017

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Journal: Oncotarget

Published: July 14, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026